Local 12: Report: Person was 'cured' of HIV, but a local doctor says treatment is dangerous
UC expert has concerns about stem cell transplants
New research published in the Nature Medicine journal says a 53-year-old German man is now clear of HIV after a procedure that replaced his bone marrow cells with HIV-resistant stem cells from a donor. He is just the third person to be cured of HIV.
WKRC-TV, Local 12, interviewed Carl Fichtenbaum, MD, of the Division of Infectious Diseases at the University of Cincinnati College of Medicine, who was at the scientific meeting in Seattle where this research was released.
"I do hope in my professional lifetime will be able to see him the situation where we can cure a disease like HIV,” said Fichtenbaum. "Every year, we get a little bit closer to a better answer.”
/content/dam/uc/news/ahc-public-relations/medicine/fichtenbaum-lab-folder.jpg/Photo/Colleen Kelley/UC Marketing + Brand
While the news about the German patient is exciting, Fichtenbaum knows it doesn't do much for the average person living with the virus.
"It’s very important, it gives us hope, but it’s not a scalable cure that can be down at your local pharmacy tomorrow," said Fichtenbaum.
That is mostly because of how specific the patient's health condition is and because Fichtenbaum says operations like stem cell transplants are extremely dangerous.
"We have tried this several times and it’s failed because bone marrow transplant transplants, stem cell transplants are dangerous, and these are mostly used in individuals who have cancer,” said Fichtenbaum.
Lead photo/Aaron Ufumeli/EPA-EFE
Next Lives Here
The University of Cincinnati is classified as a Research 1 institution by the Carnegie Commission and is ranked in the National Science Foundation's Top-35 public research universities. UC's graduate students and faculty investigate problems and innovate solutions with real-world impact. Next Lives Here.
Related Stories
Cancer Center plays key role in lab research, clinical trials for new pancreatic cancer drug
September 1, 2026
WLWT and WCPO highlighted the contributions of University of Cincinnati Cancer Center researchers that helped lead to the recent FDA approval of daraxonrasib, a new treatment for pancreatic cancer.
An expert pieced together this Roman document like a puzzle
September 1, 2026
National media highlighted a new project by UC Classics Assistant Professor Matthijs Wibier to piece together and translate an ancient Roman text from fragments buried in the desert for more than 1,600 years.
Cancer Center physician receives $150,000 New Investigator Research Grant to study treatment-resistant leukemia
September 1, 2026
The University of Cincinnati Cancer Center’s Sarah Skuli, MD, PhD, received a two‑year, $150,000 Leukemia Research Foundation New Investigator Grant to study TP53‑mutated leukemia, a treatment‑resistant subtype with very poor outcomes.